Association of rheumatoid arthritis with Mdm2 SNP309 and genetic evidence for an allele-specific interaction between MDM2 and p53 P72R variants: A case control study

Clinical and Experimental Rheumatology

Volumn 27, Issue 4, 2009, Pages 615-619

  Assmann, Gunter ^a   Voswinkel, J ^a   Mueller, M ^a   Bittenbring, J ^a   Koenig, J ^c   Menzel, A ^b   Pfreundschuh, M ^a   Roemer, K ^a   Melchers, I ^d  

^a SAARLAND UNIVERSITY   (Germany)

^b Laboratoires Reunis Kutter Lieners Hastert Centre Langwies   (Luxembourg)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d UNIVERSITY OF FREIBURG   (Germany)

Author keywords

MDM2; p53; Polymorphism; Rheumatoid arthritis; Transcription factor

Indexed keywords

GENOMIC DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN MDM2; PROTEIN P53;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE INTERACTION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION MAPPING; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; AGED; ALLELES; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 70350181570     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. HARRIS ED JR: Rheumatoid arthritis. Pathophysiology and implications for therapy. N Engl J Med 1990; 322: 1277-1289 (Pubitemid 20152491)
2. FIRESTEIN GS: Evolving concepts of rheumatoid arthritis. Nature 2003; 423: 356-361
3. GOUGH AK, LILLEY J, EYRE S, HOLDER RL, EMERY P: Generalised bone loss in patients with early rheumatoid arthritis. Lancet 1994; 344: 23-27 (Pubitemid 24199420)
4. GOLDRlNG SR, GRAVALLESE EM: Pathogenesis of bone erosions in rheumatoid arthritis. Curr Opin Rheumatol 2000; 12:195-199 (Pubitemid 30238387)
5. OSPELT C, NEIDHART M, GAY RE, GAY S: Synovial activation in rheumatoid arthritis. Front Biosci 2004; 9: 2323-2334
6. YAMANISHI Y, FIRESTEIN GS: Pathogenesis of rheumatoid arthritis: The role of synoviocytes. Rheum Dis Clin North Am 2001; 27: 355-371 (Pubitemid 32488710)
7. VOGELSTEIN B, LANE D, LEVINE AJ: Surfing the p53 network. Nature 2000; 408: 307-310
8. GUDKOV AV, KOMAROVA EA: Dangerous habits of a security guard: The two faces of p53 as a drug target. Hum Mol Genet 2007; 16: 67-72.
9. FIRESTEIN GS, MANNING AM: Signal transduction and transcription factors in rheumatic disease. Arthritis Rheum 1999; 42: 609-621
10. WARSTAT K, PAP T, KLEIN G, GAY S, AICHER WK: Co-activation of synovial fibroblasts by laminin-111 and transforming growth factor-beta induces expression of matrix metalloproteinases 3 and 10 independently of nuclear factor-kappaB. Ann Rheum Dis 2008; 67: 559-562
11. SIOUD M, MELLBYE O, FØRRE O: Analysis of the NF-kappa B p65 subunit, Fas antigen, Fas ligand and Bcl-2-related proteins in the synovium of RA and polyarticular JRA. Clin Exp Rheumatol 1998; 16: 125-134
12. BOND GL, HU W, BOND EE et al.: A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004; 119: 591-602.
13. DUMONT P, LEU JI, DELLA PIETRA AC 3RD, GEORGE DL, MURPHY M: The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003; 33: 357-365
14. ASSMANN G, WIECZOREK S, WIBISONO D, ROEMER K, ARNING L, VOSWINKEL J: The p53 G72C and MDM2 T309G single nucleotide polymorphisms in patients with Wegener's granulomatosis. Clin Exp Rheumatol 2008; 26 (Suppl. 49): 72-75
15. nd ed., New York, Wiley, Section 3.6; 2000: 70-74
16. YAMANISHI Y, BOYLE DL, PINKOSKI MJ et al.: Regulation of joint destruction and inflammation by p53 in collagen-induced arthritis. Am J Pathol 2002; 160: 123-130
17. BAIER A, MEINECKEL I, GAY S, PAP T: Apoptosis in rheumatoid arthritis. Curr Opin Rheumatol 2003; 15: 274-279
18. LEE YH, KIM YR, JI JD, SOHN J, SONG GG: P53 codon 72 polymorphism and rheumatoid arthritis. J Rheumatol 2001; 28: 2392-2394 (Pubitemid 33031966)
19. TAUBERT H, THAMM B, MEYE A et al.: The p53 status in juvenile chronic arthritis and rheumatoid arthritis. Clin Exp Immunol 2000; 122: 264-269 (Pubitemid 30839104)
20. MACCHIONI P, NlCOLI D, CASALI B et al.: The codon 72 polymorphic variants of p53 in Italian rheumatoid arthritis patients. Clin Exp Rheumatol 2007; 25: 416-421 (Pubitemid 47091018)
21. TARANTO E, XUE JR, LACEY D et al.: Detection of the p53 regulator murine double-minute protein 2 in rheumatoid arthritis. J Rheumatol 2005; 32: 424-429
22. WAWRZYNOW B, ZYLICZ A, WALLACE M et al: MDM2 chaperones the p53 tumor suppressor. J Biol Chem 2007; 282: 32603-32612 (Pubitemid 350159272)
23. ØRSTED DD, BOJESEN SE, TYBJAERGHANSEN A, NORDESTGAARD BG: Tumor suppressor p53 Arg72Pro polymorphism and longevity, cancer survival, and risk of cancer in the general population. J Exp Med 2007; 204: 1295-1301